R&D, RISK, AND PERFORMANCE IN THE SPANISH PHARMACEUTICAL INDUSTRY: A STRATEGIC GROUP ANALYSIS

被引：2

作者：

Suarez-Serrano, Eugenia ^{[1
]}

Pina-Mavarez, Enzo ^{[2
]}

机构：

[1] Univ Oviedo, Business Adm Dept, Gijon 33203, Spain

[2] Univ Andes, Pharm Dept, Merida 5101, Venezuela

来源：

INTERNATIONAL JOURNAL OF INNOVATION AND TECHNOLOGY MANAGEMENT | 2011年 / 8卷 / 02期

关键词：

Strategic groups; firm performance; pharmaceutical industry; R&D; risk; Spain;

D O I：

10.1142/S0219877011002337

中图分类号：

C93 [管理学];

学科分类号：

12 ; 1201 ; 1202 ; 120202 ;

摘要：

This paper shows an analysis of strategic groups in the Spanish pharmaceutical industry. The first results reveal that differences between company performance and strategic groups do not exist. However, taking into account the innovative process in the pharmaceutical industry, when considering the risk-adjusted results we have confirmed the existence of differences among the strategic groups for some of the used indicators. The combination of radical and low-impact innovations, production for third parties, and commercialization under licenses can offer a better performance than other groups focused exclusively in innovation or in specific market segments.

引用

页码：191 / 210

页数：20

共 50 条

[1] Strategic groups, levels of risk and business performance. An analysis of the Spanish pharmaceutical industry
Pina Mavarez, Enzo
Suarez Serrano, Eugenia
[J]. VISION GERENCIAL, 2009, 8 : 155 - 168
[2] R&D EFFECTIVENESS IN THE PHARMACEUTICAL INDUSTRY
Konopielko, Lukasz
Trehubova, Anastasiia
[J]. ECONOMIC AND SOCIAL DEVELOPMENT (ESD 2018): 33RD INTERNATIONAL SCIENTIFIC CONFERENCE ON ECONOMIC AND SOCIAL DEVELOPMENT "MANAGERIAL ISSUES IN MODERN BUSINESS", 2018, : 287 - 296
[3] Leading R&D in the pharmaceutical industry
Scolnick, EM
[J]. RESEARCH-TECHNOLOGY MANAGEMENT, 2000, 43 (03) : 35 - 38
[4] R&D and firm performance: evidence from the Indian pharmaceutical industry
Sharma, Chandan
[J]. JOURNAL OF THE ASIA PACIFIC ECONOMY, 2012, 17 (02) : 332 - 342
[5] Agency and strategic contracts: Theory and evidence from R&D agreements in the pharmaceutical industry
Guo, Di
Hua, Xinyu
Jiang, Kun
[J]. INTERNATIONAL JOURNAL OF INDUSTRIAL ORGANIZATION, 2017, 54 : 37 - 64
[6] The case for entrepreneurship in R&D in the pharmaceutical industry
Douglas, Frank L.
Narayanan, V. K.
Mitchell, Lesa
Litan, Robert E.
[J]. NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (09) : 683 - 689
[7] MANAGING RISK IN PHARMACEUTICAL R&D
Case, Randolph H.
[J]. RESEARCH-TECHNOLOGY MANAGEMENT, 2010, 53 (02) : 24 - 32
[8] Marketing/R&D integration in the pharmaceutical industry
Becker, MC
Lillemark, M
[J]. RESEARCH POLICY, 2006, 35 (01) : 105 - 120
[9] The case for entrepreneurship in R&D in the pharmaceutical industry
Frank L. Douglas
V. K. Narayanan
Lesa Mitchell
Robert E. Litan
[J]. Nature Reviews Drug Discovery, 2010, 9 : 683 - 689
[10] An assessment of R&D productivity in the pharmaceutical industry
Dimitri, Nicola
[J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2011, 32 (12) : 683 - 685

← 1 2 3 4 5 →